There are two types of insulin-like growth factor (IGF) receptors. The type I receptor generally binds IGF-I more tightly than IGF-II and also interacts weakly with insulin. The type II receptor prefers IGF-II over IGF-I and does not recognize insulin. The type I receptor is made up of an alpha binding subunit (Mr 130000) and a beta subunit (Mr 95 000) probably organized as a heterotetramer (Oizfh)■ The type II receptor consists of a single binding unit (Mr 250000). IG F stimulates phosphorylation of the beta subunit of the type I receptor in whole cells and solubilized receptor preparations. Tyrosine kinase activity is associated with the type I receptor, resulting in autophosphorylation of the beta subunit and phosphorylation of exogenous substrates. In contrast, phosphorylation of the type II receptor in whole cells is less IGF-dependent, solubilized receptor preparations are not phosphorylated, and purified type II receptors do not exhibit tyrosine kinase activity toward the artificial substrate poly(Glu,Tyr)4:1. There are many similarities between the type I IG F receptor and the insulin receptor; however, different ligand-binding properties, subtle differences in the size of alpha and beta subunits, and immunoreactivity toward anti-receptor antibodies allow us to distinguish between these two receptors. The presence of both IG F receptors as well as insulin receptors on most cells and cross-reactivity of ligands for binding to these receptors present difficulties in assigning a particular biological response to a specific receptor. The type I receptor is down-regulated by ligand while in several cell types the type II receptor is rapidly up-regulated by insulin; the mechanism of up-regulation appears to be a translocation of type II receptors to the cell surface. There are two classes of serum binding proteins for IG F, a M t 150 000 species found in adult blood and a M x 40 000 species, which predominates in foetal blood. Like the type II receptor, IG F binding proteins do not bind insulin. The binding site on the type II receptor can be distinguished from the binding protein sites by a hybrid molecule AjnsuH n-BiGF-i) which recognizes the binding protein but not the type II receptor. Binding proteins produced by cells in culture may cause confusion in the interpretation of experiments that are designed to study the binding of radiolabelled IG F to cell surface receptors in monolayer culture.
INTRODUCTION
The insulin-like growth factors (IG F ) and insulin are closely related as shown originally by amino acid sequence data (Rinderknecht & Humbel, 1978a,b) and more recently by cD N A cloning and sequencing results (Jansen et al. 1983; D ull, G ray, Hayflick & Ullrich, 1984; Bell et al. 1984; Whitfield et al. 1984) . Insulin, IG F -I and IG F -II are capable of eliciting the same biological responses including cell multiplication in tissue culture, suggesting that they have similar or identical effector pathways. On the cell surface there are two types of I G F receptors in addition to the well-described insulin receptor. Interestingly, one of the IG F receptors (type I) closely resembles the insulin receptor. In this paper we will briefly review the present state of knowledge of the IG F receptors, including receptor structure, phosphorylation, function and regulation.
EARLY COMPETITIVE BINDING DATA; EVIDENCE FOR RECEPTOR HETEROGENEITY Before it was recognized that somatomedin A, somatomedin C and IG F -I were different names for the same polypeptide, and that multiplication stimulating activity (M SA ) was the rat homologue of human IG F -II, data generated from binding of these various radioligands to intact cells and membrane preparations in competitive binding experiments showed two distinct patterns of reactivity with insulin.
In the case of the binding of [1 2 5 I] SM -C to human placental membranes (M arshall et al. 1974) , insulin completely inhibited IG F tracer binding whereas insulin competed only partially for binding of a radiolabelled preparation of non-suppressible insulin-like activity (mixture of IG F -I and IG F -II) to purified rat liver m embranes (Megyesi et al. 1974) . More subtle evidence for receptor heterogeneity emerged from a comparison of the potencies of IG F -I and IG F -II for competition for the binding of these radioligands to the same cell line (B R L 3A2) (Rechler et al. 1980 ). When IG F -I was the radioligand, IG F -I competed more potently than IG F -II whereas when binding of [1 2 5 I]IG F -II was examined, IG F -II competed more potently than IG F -I. Interestingly, competition by insulin was associated with the binding site that preferred IG F -I and insulin insensitivity was characteristic of the binding site that preferred IG F -II (Table 1) .
STRUCTURE
T h e structural basis of the different binding patterns was provided by chemical cross-linking studies in which radiolabelled IG F -I and IG F -II were allowed to bind Van Obberghen, Nissley & Rechler, 1981; Bhaumick, Bala & Hollenberg, 1981) ; the size of the receptor with disulphide bonds intact was > 3 0 0 0 0 0 (Chernausek, Jacobs & Van Wyk, 1981; M assague & Czech, 1982) . In contrast, the size of the receptor that preferred IG F -II over IG F -I and did not recognize insulin (type II) was 220000 M r without reduction and 260000 M r with reduction (T able 1; Fig. 1 ) (Massague, Guillette & Czech, 1981; K asuga et al. 1981; M assague & Czech, 1982 T h e type II receptor has been purified to homogeneity from rat chondrosarcoma cells (August et al. 1983) and rat placental membranes (Oppenheimer & Czech, 1983) . When analysed on S D S /P A G E with silver staining for protein, the M r of the receptor preparation (250 0 with the type I receptor showed weak labelling of an M r 90 000-98 000 species in addition to the more heavily labelled M x 130000 alpha subunit (Chernausek et al. 1981; M assague & Czech, 1982) , the strongest support for the existence of a beta subunit in the type I receptor came from biosynthetic and cell surface labelling experiments. Jacobs, K ull & Cuatrecasas (1983a) immunoprecipitated biosynthetically labelled or cell surface labelled receptor using monoclonal antibodies specific for the type I receptor. In addition to the alpha subunit, a 92000-98 000 M r species was identified (beta subunit).
PHOSPHORYLATION
Given the structural similarities between the insulin receptor and the type I IG F receptor it was of obvious interest to determine whether the type I I G F receptor was phosphorylated as had been shown for the insulin receptor. Jacobs et al. (19836) used a specific monoclonal antibody to the type I receptor to demonstrate phos phorylation of the type I receptor. T he A T P pool of IM-9 lymphocytes was labelled with H 3 3 2 P0 4 before the cells were incubated with IG F -I. T he cells were solubilized and glycoproteins isolated on a wheat-germ lectin Sepharose column. T ype I receptors were immunoprecipitated with the specific monoclonal antibody and the immunoprecipitate analysed by S D S /P A G E and autoradiography. IG F -I stim u lated the phosphorylation of the beta subunit of the type I receptor. Cell-free phosphorylation of the beta subunit of the type I receptor was demonstrated using a solubilized glycoprotein fraction from unlabelled IM-9 lymphocytes. T he solubilized receptor preparation was incubated with IG F -I and then [3 2 P ]A T P was added. A monoclonal antibody specific for the type I receptor was used for immunoprécipi tation and the immunoprecipitate was analysed by S D S /P A G E . Upon addition of as little as 2-5 n gm l-1 of IG F -I, phosphorylation of the type I receptor was increased. Phosphoamino acid analysis indicated that phosphorylation was occurring on tyro sine residues. Rubin, Shia & Pilch (1983) also demonstrated IG F-I-dependent phosphorylation of the type I receptor using a solubilized receptor preparation from human placenta that contained both type I IG F receptors and insulin receptors. T he concentration of IG F -I (3 nM) required for half-maximal stimulation of beta subunit phosphorylation coincided with the concentration of IG F -I required for halfmaximal inhibition of [1 2 SI] IG F -I binding. Also, monoclonal antibody specific for the type I receptor immunoprecipitated the 90000 M T species. T hese results suggest that IG F-I-stim ulated phosphorylation of the beta subunit of the type I receptor by binding to the type I receptor rather than by interacting with the insulin receptor.
Zick et al. (1984) and Sasaki et al. (1985) have studied the phosphorylation of an artificial tyrosine containing substrate p o ly (G lu ,T y r)4 :1 by a solubilized receptor preparation containing type I and type II IG F receptors. T h e receptors were prepared from B R L 3A2 rat liver cells, a cell line that has type I and type II receptors but few insulin receptors, by solubilization of a 1 0 0 0 0 0 £ membrane fraction and wheat-germ lectin affinity chromatography. IG F -I produced half-maximal stim u lation of phosphorylation of p o ly (G lu ,T y r)4 :1 and the beta subunit at 3nM; insulin was several-fold less potent. These results are consistent with intrinsic tyrosine kinase activity of the type I receptor resulting in IG F -I stimulated auto phosphorylation of the beta subunit and phosphorylation of tyrosine-containing substrates. Sasaki et al. (1985) showed that phosphorylation of the type I receptor resulted in activation of tyrosine-kinase activity as had been shown previously for the insulin receptor (Rosen et al. 1983 ). In addition, cation requirements and substrate specificities were very similar for the two receptor-associated kinase activities.
We have recently demonstrated that the type II receptor is also phosphorylated in intact cells (Haskell et al. 1985) . T he A T P pools of monolayer cultures of H-35 rat hepatoma cells, B R L 3A2 rat liver cells, Swarm rat chondrosarcoma cells and rat embryo fibroblasts were labelled with H 3 3 2 P0 4 -Cell monolayers were solubilized with detergent, glycoproteins purified by wheat-germ lectin Sepharose affinity chromatography and the type II receptor isolated by IG F -II affinity chroma tography. Analysis by S D S /P A G E and autoradiography revealed a phosphorylated species with the M x expected for the type II receptor. We examined the IG F dependence of the phosphorylation of the type II receptor in rat embryo fibroblasts and B R L 3A2 cells. In rat embryo fibroblasts phosphorylation of the type II receptor was not increased by addition of IG F -II to the cultures. However, rat embryo fibroblasts produce IG F -II, which could potentially autostimulate phosphorylation of the type II receptor. In B R L 3A2 cells that do not produce IG F -II, addition of IG F -II resulted in increased phosphorylation of the type II receptor. Lability of the phosphate-receptor bonds at alkaline pH suggested that phosphorylation was occur ring primarily on serine residues. T he level of basal phosphorylation of the type II receptors in B R L 3A2 cells was variable, however, suggesting that other factors in addition to IG F control type II receptor phosphorylation. It has not been possible to demonstrate phosphorylation of the type II receptor in cell-free preparations. T hu s when a solubilized glycoprotein preparation containing both type I and type II receptors was incubated with IG F and [3 2 P ]A T P only the type I receptor was phosphorylated (Zick et al. 1984; Sasaki et al. 1985) . Similarly,
we were unable to demonstrate phosphorylation of p o ly (G lu ,T y r)4 :1 using a purified type II receptor preparation from chondrosarcoma cells together with [3 2 P ]A T P and IG F -I; in the same experiment a solubilized type I receptor preparation exhibited tyrosine kinase activity toward the tyrosine-containing su b strate (Sasaki & Haskell, unpublished results). T hu s in contrast to insulin and type I I G F receptors the type II IG F receptor appears not to possess intrinsic tyrosine kinase activity. It will be of interest to determine whether type II receptor phos phorylation observed in intact cells plays a role in receptor function or regulation.
SIMILARITY OF THE TYPE I IGF RECEPTOR AND THE INSULIN RECEPTOR
T able 2 outlines the many similarities between the type I IG F receptor and the insulin receptor, some of which have been described earlier in this paper. Although both receptors contain alpha and beta subunits there is evidence for small differences in the size of these common subunits when comparing type I receptors and insulin receptors. Stuart, Pietrzyk, Siu & Furlanetto (1984) used simultaneous double-label affinity cross-linking of human placental type I IG F receptors (labelled with [1 2 5 I]IG F -I) and insulin receptors (labelled with [1 3 1 I]insulin) to demonstrate that the type I receptor alpha subunit was 8000 in M t smaller than the alpha subunit of the insulin receptor. Experiments in which biosynthetically labelled and surface-labelled insulin and IG F receptors were immunoprecipitated with specific monoclonal anti bodies and analysed by S D S /P A G E , showed that the beta subunit of the type I receptor was larger than the beta subunit of the insulin receptor (Jacobs et al.
1983a). T he relative contributions of protein and carbohydrate moieties to these size differences are not known.
Biosynthetic labelling experiments in IM-9 lymphocytes in which processing was blocked with monensin revealed a similar-sized M v 180000 precursor for the type I I G F receptor and the insulin receptor (Jacobs et al. 1983a) . Analagous to the insulin receptor, the M T 180000 type I IG F receptor precursor is presumed to be made up of contiguous alpha and beta subunits. Experim ents with polyclonal and monoclonal antibodies to type I I G F receptors and insulin receptors point to similar antigenic determinants on the two receptors. U sing a panel of sera from patients with autoantibodies to the insulin receptor, K asu ga et al. (1983) showed that each of seven sera also recognized the type I I G F (1985) have deduced the primary structure of the insulin receptor by cloning and sequencing the cD N A for the insulin receptor. There is one transmembrane region that is in the beta subunit; the alpha subunit appears to be entirely extracellular. There is sequence homology between regions of the cyto plasmic domain of the beta subunit and members of the src family of tyrosine-specific protein kinases and even more extensive homology with the avian sarcoma virus U R 2 oncogene v-tvs. Given all the similarities between the insulin receptor and the type I I G F receptor listed in T able 2, it is expected that the type I I G F receptor primary structure will resemble the insulin receptor in its essential features.
RECEPTOR FUNCTION M ost cells have both types of IG F receptors as well as insulin receptors (Rechler & N issley, 1985). IG F -I, IG F -II and insulin can interact with both insulin receptors and type I IG F receptors; only IG F -I and IG F -II interact with the type II receptor.
Because of this extensive cross-reactivity of ligands with these three receptor types it is difficult to assign particular biological responses to specific receptors. Com parison of dose-response curves for eliciting a biological response with competitive binding curves have been helpful but in most cases not conclusive. In chick embryo fibroblasts the dose-response curves of rat IG F -II, insulin and proinsulin for stimulation of D N A synthesis were superimposable on binding curves for inhibition of IG F -II tracer binding (Nissley et al. 1977) . These data together with the failure to demonstrate a type II receptor on these cells lead to the conclusion that stimulation of D N A synthesis by IG F and insulin in chick embryo fibroblasts proceeds via the type I receptor. Indeed the requirements for high concentrations of insulin for the growth of many cells in defined media suggest that the type I IG F receptor rather than the insulin receptor may be involved in the growth response. Exceptions to this generalization are found in H-35 rat hepatoma (Koontz & Iwahashi, 1981; Koontz, 1984) and F9 mouse teratocarcinoma cells (Nagarajan & Anderson, 1982) where physiological rather than pharmacological concentrations of insulin stimulate D N A synthesis. By doing appropriate experiments using antisera directed against the insulin receptor it has been demonstrated that insulin is acting as a mitogen through the insulin receptor in these cells.
Insulin receptor antisera were also used to demonstrate that IG F -II stimulates glucose oxidation in rat adipocytes by acting through the insulin receptor rather than via the type II receptor, which is also present on these cells (K ing, K ahn, Rechler & N issley, 1980 T h e type I IG F receptor is down-regulated following prolonged incubation with ligand in IM-9 lymphocytes (Rosenfeld, Hintz & Dollar, 1982) , human fibroblasts (Rosenfeld & Dollar, 1982) and B C 3 H-I mouse muscle cells (D e Vroede et al. 1984) .
In contrast, the type II receptor is not down-regulated in rat chondrosarcoma cells (Stevens, Austen & Nissley, 1983) , B C 3 H -I mouse muscle cells (D e Vroede et al. 1984) and H T C rat hepatoma cells (Heaton et al. 1984) .
Brief incubation of rat adipocytes or H-35 rat hepatoma cells with insulin leads to a rapid increase in IG F -II binding to the type II receptor (Schoenle, Z apf & Froesch, 1976; K ing, Rechler & Kahn, 1982; Oppenheimer et al. 1983) . Agonistic auto antibodies to the insulin receptor duplicated this effect and Fab fragments of these autoantibodies blocked insulin-stimulated increase in IG F -II binding in rat ad ipocytes (K in g et al. 1982) . T hus the up-regulation of the type II receptor by insulin appears to occur by interaction with the insulin receptor. Tw o types of experimental approach have led to the conclusion that this up-regulation of the type II receptor by insulin results from cycling of type II receptors from an intracellular compartment to the cell surface. T hu s insulin treatment of rat adipocytes resulted in increased binding of a type II receptor polyclonal antibody to the cell surface (Oka, M ottola, Oppenheimer & Czech, 1984) . In a second approach, following exposure of the adipocytes to insulin, receptor endocytosis was blocked with K C N and IG F -II binding was analysed according to the method of Scatchard (Wardzala, Sim pson, Rechler & Cushman, 1984) . Insulin caused a fivefold stimulation in type II receptor number with no change in binding affinity.
IGF BINDING PROTEINS AND IGF RECEPTORS
Unlike insulin, IG F -I and IG F -II are found complexed to larger binding proteins in serum and other extracellular fluids (Hintz, 1984; Nissley & Rechler, 1985) . T he association of IG F with binding proteins extends to tissue culture system s; although there are examples of cells producing binding protein without producing IG F , the reverse situation has not been described.
There appear to be two classes of IG F binding proteins in serum. A small (MT 40 000) binding protein is the predominant binding protein in foetal blood (D 'Ercole, Willson & Underwood, 1980; White et al. 1982) , whereas in adult blood the major carrier of IG F is an M r 150 000 species, which is partially under the control of pituitary growth hormone (White et al. 1981) . T he 150 000 M t species is m ade up of subunits. One model for 150000 M t binding protein structure proposes that a 40 000M r acid-stable binding subunit is complexed to a larger acid-labile component, which does not bind IG F (Furlanetto, 1980) . A more recent model describes the 150 000 M t species as simply being an oligomer of a binding subunit of 24 000-28 000 M v (Wilkins & D 'Ercole, 1985) . Binoux, Hardouin, Lassarre & H ossenlopp (1982) have provided competitive binding data that suggest that within the 150000 and 40 000 M r classes of IG F binding proteins there may be species which prefer IG F -I over IG F -II and vice versa.
T he role of the binding proteins has not been defined. T he binding proteins appear to prolong the half-life of circulating IG F and thus may constitute both a reservoir and a system for delivery and release of IG F to tissues. Although, on the basis of experiments in which acid-treated binding proteins (free of IG F ) were shown to inhibit bioactivity of IG F in systems in vitro (Zapf et al. 1979; D rop et al. 1979; K nauer & Smith, 1980) it has been assumed that the bound forms of I G F are biologically inactive, a purified native IG F binding protein complex has not been available for testing.
What is the relation, if any, between IG F binding proteins and cell surface receptors? On the basis of binding properties the type I IG F receptor is distinct from binding proteins. Whereas insulin binds to the type I receptor, insulin has con sistently not competed for IG F tracer binding to binding proteins. T he type II receptor also does not recognize insulin. Recently, a hybrid molecule containing the B domain of IG F -I and the A domain of insulin (A in^n -B^p .!) has been shown to recognize binding proteins from a variety of sources but not to interact with the type II receptor, indicating that the binding site of the type II receptor and the binding site of certain binding proteins are different (D e Vroede et al. 1985a) .
For in vitro studies of the binding of IG F tracer to receptors on cells and membranes, binding proteins present a potential problem in the interpretation of data. F or example, Grizzard et al. (1984) showed that human placental membranes prepared by differential centrifugation contained a small molecular weight binding protein that could only be removed by extensive washing. Presumably this binding protein represented a contaminant from amniotic fluid and, or, plasm a. In monolayer cultures of human skin fibroblasts binding protein released to the media during the binding incubation may produce complex competitive binding curves. Cell-associated binding protein may potentially account for some binding of IG F tracer to the monolayer (D e Vroede, Katsoyannis & Rechler, 19856) .
CONCLUSIONS M ajor differences between type I and type II IG F receptors raise the possibility that these receptors will be found to be coupled to different post-receptor events. In contrast, the similarities between the insulin receptor and the type I IG F receptor are striking, and suggest that, like insulin and IG F s, these two receptors may have evolved from a common ancestral gene.
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